SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004; 22: 2061-2068.
  • 2
    Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14: 1858-1867.
  • 3
    Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999; 17: 3403-3411.
  • 4
    Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993; 32: 235-242.
  • 5
    Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol. 1997; 40: 245-250.
  • 6
    Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994; 12: 1621-1629.
  • 7
    Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14: 1877-1884.
  • 8
    Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. New York: Chapman & Hall/CRC; 2000.
  • 9
    Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 10
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
  • 11
    Cox D. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
  • 12
    Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526.
  • 13
    Therneau PM Therneau TM. Modeling Survival Data. New York: Springer; 2000.
  • 14
    Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998; 16: 3353-3361.
  • 15
    Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001; 19: 4216-4223.
  • 16
    Sato K, Inoue K, Saito T, et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol. 2003; 33: 371-376.
  • 17
    Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004; 90: 285-288.
  • 18
    Gori S, Mosconi AM, Basurtol C, et al. Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori. 2002; 88: 470-473.
  • 19
    Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008; 26: 1642-169.
  • 20
    Verrill MW, Lee J, Cameron DA, et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol. 2007; 25: 33s.